findmyKOL

Patrick Ryscavage, MD

Basic profile

University of Maryland, Baltimore

ORCIDNPI
RegionBaltimore, MD · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Patrick Ryscavage is an Infectious Disease physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 35 publications with 971 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
35publications

Distinct works indexed by OpenAlex, matched via ORCID.

971citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    48.5%
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor22%
    Triumeq45%Descovy42%Abacavir-Lamivudine13%
    Part D<11 patients
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor19.9%
    Tivicay56%Dovato44%
    Part D<11 patients

    + 3 more classes in this area

  • Cardiovascular

    32%
    Statin8.8%
    Atorvastatin Calcium59%Rosuvastatin Calcium41%
    Part D<11 patients
    Calcium channel blocker6.2%
    Amlodipine Besylate67%Nifedipine Er33%
    Part D<11 patients

    + 7 more classes in this area

  • Respiratory

    9%
    beta2-Adrenergic Agonist5.2%
    Albuterol Sulfate Hfa56%Ventolin Hfa44%
    Part D<11 patients
    RNA Synthetase Inhibitor Antibacterial2.3%
    Mupirocin100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”